RC

R. Cory

SVP, Head of Corporate Affairs & Investor Relations

Ovid Therapeutics

Ovid Therapeutics Pipeline

DrugIndicationPhase
OV329Treatment-resistant seizuresPhase 1
OV350Undisclosed CNS disordersPreclinical
OV882SYNGAP1-related intellectual disabilityResearch
OV4071Undisclosed CNS disordersResearch
Soticlestat (OV935/TAK-935)Dravet Syndrome, Lennox-Gastaut SyndromePhase 3